Ras peptide-specific vaccination in patients with non-small cell lung cancer (NSCLC) Source: Annual Congress 2006 - Lung cancer treatment Year: 2006
Proliferative activity of non-small cell lung cancer after induction chemotherapy Source: Eur Respir J 2005; 26: Suppl. 49, 328s Year: 2005
Clinical usefulness of natural killer cell activity in patients with non-small cell lung cancer Source: International Congress 2018 – Lung cancer: novel prognostic markers and scores Year: 2018
IRP2 as a potential modulator of cell proliferation, apoptosis and prognosis in nonsmall cell lung cancer Source: Eur Respir J , 49 (4) 1600711; DOI: 10.1183/13993003.00711-2016 Year: 2017
XAGE-1b and p53: Potential targets for immunotherapy of non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012
p53 mutations do not predict response to paclitaxel in metastatic non-small cell lung carcinoma Source: Annual Congress 2009 - Lung cancer biology Year: 2009
Inhibition of autophagy potentiates pemetrexed and simvastatin-induced apoptotic cell death in malignant mesothelioma and non-small cell lung cancer cells Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers Year: 2015
Deguelin enhances chemosensitivity of non-small cell lung cancer cells Source: Eur Respir J 2006; 28: Suppl. 50, 336s Year: 2006
CHD4 is associated with poor prognosis of non-small cell lung cancer patients through promoting tumor cell proliferation Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016
New treatment options for nonsmall cell lung cancer and small cell lung cancer Source: Annual Congress 2006 - PG12 - Small cell lung cancer management Year: 2006
Immunotherapy for nonsmall cell lung cancer: a new therapeutic algorithm Source: Eur Respir J, 55 (2) 1901907; 10.1183/13993003.01907-2019 Year: 2020
Second line therapy for advanced non-small cell lung cancer Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009
The influence of conventional and targeted chemotherapy on the expression of stem cell markers in lung cancer cell lines Source: International Congress 2017 – Lung cancer: latest basic research on molecular alterations, tumour-immune system-microenvironment interplay and the metabolome Year: 2017
Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy Source: Eur Respir J, 53 (3) 1801562; 10.1183/13993003.01562-2018 Year: 2019
HIF-1α modulation by topoisomerase inhibitors in A549, a non-small cell lung cancer cell line Source: Annual Congress 2007 - Biology in thoracic oncology Year: 2007
Clinical implication of stem cell markers in N2 positive non-small cell lung cancer Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012
Clinical characterization of non-small cell lung cancer tumors showing neuroendocrine differentiation Source: Eur Respir J 2002; 20: Suppl. 38, 270s Year: 2002
Shikonin-induced necroptosis is enhanced by the inhibition of autophagy in non-small cell lung cancer cells Source: International Congress 2016 – Basic science and case reports in lung cancer Year: 2016
Management of extensive disease-small cell lung cancer Source: Eur Respir Mon; 2009: 44: 310–317 Year: 2009
Nuclear and microenvironment interactions could be useful biological prognostic markers for adjuvant therapy in advanced non-small cell lung carcinoma Source: Eur Respir J 2002; 20: Suppl. 38, 72s Year: 2002